Molecular profiling of tumors has expanded the treatment options for patients with a wide variety of high prevalence cancers and cancers associated with high death rates, such as lung, colon, prostate, and breast. Overall, combining genetic testing with targeted therapies is extending survival while minimizing adverse effects.
This webinar will bring together leading experts in molecular pathology, NGS tumor profiling, companion diagnostics development, and precision oncology for a panel discussion. The panelists will discuss topics including today’s achievements advancing precision diagnostics and how to address the many unmet laboratory and testing needs required to support continuous improvement of cancer patient therapy.
The panelists on this webinar are Dara L. Aisner, MD PhD, Associate Professor, Director Colorado Molecular Correlates Laboratory, Department of Pathology at the University of Colorado, George Green, PhD, Executive Director, Head Pharmacodiagnostics at Bristol-Myers Squibb, Greg Tsongalis, PhD, Director of the Laboratory for Clinical Genomics and Advanced Technologies at Theodor Geisel School of Medicine at Dartmouth and Russell Garlick, PhD, Chief Scientific Officer at LGC Clinical Diagnostics.
Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences